Author, reference (publication year) | Study design | Recruitment period | Number of patients | Median age | Sex (M/F) | Type | Conditioning regimen | GVHD prophylaxis | Interval from diagnosis to treatment (M) | Neutrophil recovery (d) | Platelet engraftment | MSCs originals | NOS score |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wang Z-K [31] (2019) | Single-arm study | January 2014-December 2016 | 35 | 11.5 (3–18) | 18/17 | SAA/VSAA (19/16) | Busulfan (Bu) + cyclophosphamide (Cy) + antithymocyte globulin (ATG) | CsA + MMF + MTX | NA | 14 (10–22) | 18 (9–36) | BM | 6 |
Yue C [32] (2018) | Cases | January 2014-January 2017 | 6 | 23 (15–31) | 3/3 | VSAA (6) | Busulfan (Bu) + cyclophosphamide (Cy) + antithymocyte globulin (rATG) | CsA + MMF + MTX | 2 (1–3.5) | 13 (9–19) | 15.5 (10–23) | BM | 5 |
Liu Z [33] (2017) | Single-arm study | March 2013-August 2015 | 44 | 24 (8–47) | 29/15 | SAA/VSAA (31/13) | Busulfan (Bu) + cyclophosphamide (Cy) + antithymocyte globulin (ATG) | CsA + MMF + MTX | 31.2 (1–249) | 12 (8–21) | 19 (8–154) | BM | 6 |
Xu L [34] (2018) | Single-arm study | June 2010-August 2013 | 24 | 16.5 (5–55) | 14/10 | SAA (24) | Cyclophosphamide (Cy) + antithymocyte globulin (rATG) + FLU or | CsA + ATG+ CD25Ab + mycophenolate material | NA | 11 (10–25) | 13 (10–25) | UC | 6 |
Wu Y [35] (2017) | Single-arm study | January 2011-June 2016 | 77 | 9 (1–46) | 39/38 | SAAVSAA/SAA and PNH (72/5) | Cyclophosphamide (Cy) + antithymocyte globulin (ATG) + FLU ± busulfan | CsA + MMF + MTX + CD25Ab | 7 (2–182) | 12(8–21) | 14 (9–30) | UC | 5 |
Li XH [36] (2014) | Single-arm study | October 2006-October 2012 | 17 | 19 (4–29) | 10/7 | SAA/VSAA (8/9) | Cyclophosphamide (Cy) + antithymocyte globulin (ATG) + FLU | CsA + MMF + CD25Ab | 3 (1–5) | 12 (11–21) | 14 (11–75) | UC | 6 |
Wu Y [37] (2014) | Single-arm study | January 2007-June 2013 | 21 | 18 (4–31) | 11/10 | SAA/VSAA/SAA and PNH (7/12/2) | Cyclophosphamide (Cy) + antithymocyte globulin (rATG) + FLU or | CsA + MMF + CD25Ab + rATG | 6 (1–128) | 12 (8–21) | 14(10–23) | UC | 6 |
Wang Z [38] (2014) | Single-arm study | March 2010-April 2013 | 17 | 10 (4–19) | 6/11 | SAA/VSAA/2 HSCT (11/5/1) | BU + fludarabine + CY + ATG | CsA + MMF + MTX + CD25Ab | 12 (1–44) | 16 (9–25) | 22 (9–95) | UC | 6 |